Skip to main content

Table 4 Regression Analysis for Grade I- Postoperative Grade I Ileus with total cohort

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 Univariate analysisMultivariate analysis
OROR 95% CIpOROR 95%CIp
Gender (M/F)1.770.97–3.10.06   
Age at surgery(years)1.010.94–1.020.94   
BMI (kg/m2)0.110.41–2.70.55   
Preoperative wt loss
(> 10 lb)a
1.050.41–2.70.92   
Disease duration (mos)0.990.99–1.020.59   
Smoking
Never
Prior0.970.47–2.00.97   
Current0.670.79–5.70.72   
Disease extent
E2 Left-sided colitis
E3 Pancolitis1.45066–3.400.34   
Disease severity
S2 Moderate UC
S3 Severe UC1.120.60–2.120.72   
Disease activity
Chronic
Acute2.831.05–7.670.043.091.11–8.610.03
Medication history
Steroids0.920.59–1.980.92   
6-MP or MTX0.530.29–0.970.040.560.28–1.070.08
IPAA stages
Total abdominal colectomy
+end stoma
Protectomy + IPAA with ileostomy1.240.65–2.400.51   
Operation type
Open
laparoscopy0.530.28–0.980.040.540.27–1.060.07
Preoperative labs
Leukocyte (×103/uL)1.001.00–1.000.45   
Platelet (×103/uL)1.010.99–1.000.34   
Albumin (g/dL)0.820.40–1.650.58   
Biologic agent
None
Anti-TNF1.760.83–3.730.142.451.08–5.590.03
Vedolizumab3.151.08–9.20.044.711.51–14.700.01
  1. OR odds ratio, CI confidence interval, BMI body mass index, 6-MP 6-mercaptopurine, MTX methotrexate, CSA cyclosporine A, IPAA ileal pouch-anal anastomosis, TNF tumor necrosis factor